JP2021515541A - Ｐｄ１結合剤 - Google Patents

Ｐｄ１結合剤 Download PDF

Info

Publication number
JP2021515541A
JP2021515541A JP2020542228A JP2020542228A JP2021515541A JP 2021515541 A JP2021515541 A JP 2021515541A JP 2020542228 A JP2020542228 A JP 2020542228A JP 2020542228 A JP2020542228 A JP 2020542228A JP 2021515541 A JP2021515541 A JP 2021515541A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
region
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515541A5 (https=
JPWO2019170898A5 (https=
Inventor
ジェームズ ジョナサン フィンレー，ウィリアム
ジェームズ ジョナサン フィンレー，ウィリアム
Original Assignee
ウルトラヒューマン ナイン リミテッド
ウルトラヒューマン ナイン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウルトラヒューマン ナイン リミテッド, ウルトラヒューマン ナイン リミテッド filed Critical ウルトラヒューマン ナイン リミテッド
Publication of JP2021515541A publication Critical patent/JP2021515541A/ja
Publication of JP2021515541A5 publication Critical patent/JP2021515541A5/ja
Publication of JPWO2019170898A5 publication Critical patent/JPWO2019170898A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020542228A 2018-03-08 2019-03-08 Ｐｄ１結合剤 Pending JP2021515541A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1803746.5 2018-03-08
GBGB1803746.5A GB201803746D0 (en) 2018-03-08 2018-03-08 PD1 binding agents
GB1813405.6 2018-08-16
GBGB1813405.6A GB201813405D0 (en) 2018-03-08 2018-08-16 PD1 binding agents
PCT/EP2019/055927 WO2019170898A1 (en) 2018-03-08 2019-03-08 Pd1 binding agents

Publications (3)

Publication Number Publication Date
JP2021515541A true JP2021515541A (ja) 2021-06-24
JP2021515541A5 JP2021515541A5 (https=) 2022-03-15
JPWO2019170898A5 JPWO2019170898A5 (https=) 2022-03-15

Family

ID=61972796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542228A Pending JP2021515541A (ja) 2018-03-08 2019-03-08 Ｐｄ１結合剤

Country Status (10)

Country Link
US (2) US10858435B2 (https=)
EP (1) EP3762419A1 (https=)
JP (1) JP2021515541A (https=)
CN (1) CN111819199A (https=)
AU (1) AU2019229676A1 (https=)
CA (1) CA3092174A1 (https=)
GB (2) GB201803746D0 (https=)
IL (1) IL277135A (https=)
SG (1) SG11202008246VA (https=)
WO (1) WO2019170898A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
AU2020366257B2 (en) * 2019-10-15 2025-01-23 Diverse Biotech, Inc. Conjugate molecules
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533763A (ja) * 2013-09-13 2016-11-04 ベイジーン リミテッド 抗ｐｄ−１抗体並びにその治療及び診断のための使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
MY184154A (en) * 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
NZ739090A (en) * 2015-10-02 2025-06-27 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
GB201803745D0 (en) 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016533763A (ja) * 2013-09-13 2016-11-04 ベイジーン リミテッド 抗ｐｄ−１抗体並びにその治療及び診断のための使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MABS, vol. 5, no. 3, JPN6023003052, 2013, pages 445 - 470, ISSN: 0004974625 *

Also Published As

Publication number Publication date
US20200332006A1 (en) 2020-10-22
IL277135A (en) 2020-10-29
GB201803746D0 (en) 2018-04-25
US20210101981A1 (en) 2021-04-08
CN111819199A (zh) 2020-10-23
SG11202008246VA (en) 2020-09-29
US10858435B2 (en) 2020-12-08
WO2019170898A1 (en) 2019-09-12
CA3092174A1 (en) 2019-09-12
EP3762419A1 (en) 2021-01-13
AU2019229676A1 (en) 2020-08-20
GB201813405D0 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
US10858435B2 (en) PD1 binding agents
JP2021519100A (ja) Ｃｄ４７結合剤
US12415861B2 (en) Anti C-MET antibodies
JP2021528973A (ja) 抗ｓｔｅａｐ１抗原結合タンパク質
JP7419238B2 (ja) Ｐｄ１結合剤
JP7689116B2 (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
JP2021515544A (ja) Ｅｒｂｂ３結合剤
US11655300B2 (en) Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof
HK40100558A (zh) C-kit结合剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230815